,34 Elevated circulating levels of galectin-3 are linked to CKD progression and myocardial dysfunction, and preclinical data suggest that galectin-3 inhibition may ameliorate cardiac abnormalities in ADPKD.13 This evidence concerns the gene LGALS3 and chronic kidney disease.